Acute Myeloid Leukemia: Research
Top Research
1. WEE1 is a critical mediator in perpetuation of cell cycle.
Leukemia, 13 January, 2012
A new molecular and computational approach combined with gene expression profiling, has enabled scientists in strongly implicating the role of a checkpoint protein WEE1 in survival of AML cells exposed to Cytarabine, a potent chemotherapeutic agent. WEE1 is a potential novel target for advanced drug discovery research and development of a new line of drugs to treat AML.
Via: Nature
2. The significance of Gene Expression Profiling in identifying prognostic subclasses in adult AML
NEJM, 14 April, 2004
New molecular subtypes of AML with distinct molecular signatures, as determined by complementary DNA microarrays of AML, are identified by using unsupervised hierarchical clustering analysis.
Via: Pulmonics
3. The role of nucleophosmin in AML initiation and progression
Activated humanized gene Npm 1c when knocked in mouse hematopoetic cells, caused one third of the mouse population to develop delayed AML. This further suggested that the delay in the onset of AML was due to lack of ‘cooperating’ mutants, later identified with the help of a transpososn named Sleeping Beauty.
Via: Nature
4. The role of a novel MLL translocation partner, KIAA1524, in AML
The Mixed Lineage Leukemia (MLL) gene is located on 11q23. It is a frequent site of translocation in AML and its promiscuity is reflected by several different translocation partners as described in the literature. In infant AML, a new translocation segment on the 13th chromosome was identified using the results of ‘fluorescent in-situ hybridization’. It has also been found that it is a gene, called KIAA1524, acting as a proto-oncogene for stabilizing MYC protein in the case of gastric carcinoma. Since KIAA1524 has never been reported to be associated with myeloid leukemia before, it is likely that a common underlying mechanism between hematologic malignancies and other kind of malignancies exist, paving the way for the development of therapeutic agents with a wider repertoire.
Via: LRJournal
5. GATA2 is significant site of mutation leading to the development of AML
Several studies have reported that mutation in GATA2 predisposes a patient to AML and Mylodisplastic Syndrome (MDS). Mutated GATA2 can therefore be considered as a potential target candidate for developing an advanced target specific therapeutic agent.
Via: Nature